Breaking News

ProBioGen, Vaccitech Ink Cell Line License Agreement

Will leverage ProBioGen’s AGE1.CR duck cell technology for large-scale manufacturing

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG and Vaccitech, Ltd. have signed a license agreement under which Vaccitech will gain access to ProBioGen’s technology platform based on the AGE1.CR duck retina cell line for production of its viral vectored vaccines. Earlier work leading to the license confirmed that the AGE1.CR duck cell technology allows large-scale manufacturing with higher production yields and lower cost of goods compared to other poxvirus production technologies.     ProBioGen’s chief scientific officer, Dr. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters